August 15, 2025

Indocyanine Green Angiography Shows Potential in Leak Prevention

The benefit might be in preventing grade A or B leaks, the researchers posited.

Conexiant

August 15, 2025

Autoimmune Diseases Tied to Different Digestive Cancer Risks

Researchers examined celiac disease, SLE, MS, and T1D in relation to cancers of the pancreas, stomach, esophagus, small intestine, colon, rectum, liver, and gallbladder.

Conexiant

August 14, 2025

Antidepressants May Benefit IBD Through Shared Mechanisms

Researchers examine how inflammatory bowel disease and depression share biological mechanisms and how treating one may improve outcomes in the other.

Conexiant

August 14, 2025

Greater Variety of Flavonoids Tied to Lower Chronic Disease

Higher diversity and quantity of dietary flavonoid intake were each linked to reduced risks of mortality and major chronic diseases in a large population-based study.

Conexiant

August 12, 2025

Biomarker Discordance in Metastatic Bowel Cancer

Researchers report HER2, HER3, and MMR expression patterns in stage IV small bowel adenocarcinoma

The Pathologist

August 08, 2025

INSL5 Rise Tied to Diarrhea Severity, Treatment

Circulating Insulin-like peptide 5 concentrations may reflect colonic exposure to bile acids and help stratify treatment response in patients with chronic diarrhea.

Conexiant

August 07, 2025

Medical Oddities: Cocoa Fights the Flu?

Chocolate fights flu, snails regrow eyes, guts go neural, and past lives go clinical.

Conexiant

August 07, 2025

Study Ties Asthma to Cardiometabolic Risk

Researchers studying nearly 29,000 middle-aged adults in Sweden found that individuals with asthma had significantly higher rates of hypertension, diabetes, and other conditions, along with elevated levels of systemic inflammation and blood sugar markers.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant